Q-omics provides the consensus-scored CHSY1 profile across patient tissues and cancer cell-line models. CHSY1 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, CHSY1 is differentially expressed in 10, with the highest sampling consensus in HNSC. Additionally, CHSY1 RNA expression shows 20,191 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and HNSC as cancer lineages where CHSY1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CHSY1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CHSY1 survival associations across molecular data types. CHSY1 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (5) and mass-spec protein abundance (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CHSY1 RNA expression–survival associations across cancer types. High CHSY1 expression shows unfavorable associations in ACC, MESO, BLCA, LGG, KIRP and SARC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for CHSY1 RNA expression.
This table summarizes CHSY1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 7. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for CHSY1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CHSY1 shows lower tumor expression in KICH and higher tumor expression in HNSC, KIRC, COAD, CHOL and STAD. The HNSC box plot shows higher CHSY1 RNA expression in tumor versus normal tissue (log2 FC = +1.381, t-test p < 0.001).
This table shows molecular features associated with CHSY1 in patient tissues and cancer cell lines. In patient samples, CHSY1 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, CHSY1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and LARGE_INTESTINE.
